FOLH1 and lung carcinoma: To study the value of PSMA as a potential new target for lung cancer treatment, we measured its expression in lung cancer tissues and then correlated its expression with patient age at the time of diagnosis, gender, clinical stage, pathological type, primary tumor size, and lymph node metastasis.